FDG Digital PET/CT as First Line Investigation for Giant Cell Arteritis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Gad Abikhzer, MD
- Phone Number: 514-340-8222
- Email: gad.abikhzer@mcgill.ca
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H4J 1C5
- Hôpital du Sacré-Cœur de Montréal
-
Montreal, Quebec, Canada, H4R3E8
- Jewish General Hospital
-
Sherbrooke, Quebec, Canada, H3T1C5
- CHUS
-
-
-
-
-
Dijon, France, 21000
- Université Bourgogne Europe, Centre Georges-François Leclerc
-
-
-
-
-
Groningen, Netherlands
- University Medical Center Groningen
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 50 years, capable and willing to provide informed consent and can tolerate PET/CT.
- ESR ≥ 50 mm/h and/or CRP ≥ 10mg/L within 1 week of PET/CT referral.
- New suspected giant cell arteritis according to at least one of the following criteria:
Cranial GCA symptoms (new-onset localized headache, scalp or temporal artery tenderness, ischemia-related vision loss, masseter pain on prolonged mastication) PMR symptoms: shoulder and/or hip girdle pain associated with inflammatory stiffness.
Suspected large-vessel vasculitis based on angiography, MRA, or CTA.
Exclusion Criteria:
- Initiation of corticosteroid or immunosuppressive therapy >4 days before PET/CT.
- Prior TAB or treated GCA with suspected relapse.
- Non-fasting or hyperglycemia (>11.1 mmol/L) resulting in altered FDG biodistribution.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnostic Performance
Time Frame: 2 years
|
of Digital PET/CT and DUS for the diagnosis of GCA
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Cerebrovascular Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Autoimmune Diseases
- Immune System Diseases
- Autoimmune Diseases of the Nervous System
- Skin Diseases
- Skin Diseases, Vascular
- Vasculitis, Central Nervous System
- Arteritis
- Skin and Connective Tissue Diseases
- Giant Cell Arteritis
- Vasculitis
Other Study ID Numbers
Other Study ID Numbers
- MP-05-2021-2846
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.